Table 3.
Time between diagnosis of uveitis and start with immunosuppressive therapy and time between diagnosis of uveitis and initial tertiary centre visit in patients with and without complications in the two different cohorts.
| Cohort 1 | p‐value | Cohort 2 | p‐value | |||
|---|---|---|---|---|---|---|
| Yes | No | Yes | No | |||
| Cataract surgery | ||||||
| Number of patients, n (%) | 36 (59) | 25 (41) | 17 (21) | 65 (79) | ||
| Time between diagnosis of uveitis and start methotrexate, median in years (IQR) | 2.5 (0.5–5.8) | 0.4 (0.0–3.3) | 0.10 | 0.0 (0.0–0.1) | 0.1 (0.0–0.7) | 0.22 |
| Time between diagnosis of uveitis and start anti‐TNFα therapy, median in years (IQR) | 7.0 (3.7–9.5) | 5.1 (3.2–7.0) | 0.45 | 1.8 (0.7–3.7) | 1.9 (0.7–4.5) | 0.85 |
| Time between diagnosis of uveitis and initial visit at tertiary centre, median in years (IQR) | 1.3 (0.7–5.5) | 3.0 (2.2–4.8) | 0.57 | 0.1 (0.0–0.9) | 0.9 (0.2–2.4) | 0.04 |
| Secondary glaucoma | ||||||
| Number of patients, n (%) | 28 (46) | 33 (54) | 9 (9) | 73 (91) | ||
| Time between diagnosis of uveitis and start methotrexate, median in years (IQR) | 2.5 (0.5–5.7) | 0.6 (0.0–3.9) | 0.16 | 0.0 (0.0–0.0) | 0.08 (0.0–0.6) | 0.02 |
| Time between diagnosis of uveitis and start anti‐TNF‐α therapy, median in years (IQR) | 8.0 (5.2–9.5) | 3.9 (2.8–5.7) | 0.19 | 1.6 (0.6–2.1) | 2.1 (0.7–4.5) | 0.54 |
| Time between diagnosis of uveitis and initial visit at tertiary centre, median in years (IQR) | 1.7 (0.9–3.3) | 4.4 (0.7–8.3) | 0.29 | 0.5 (0.1–1.3) | 0.9 (0.1–7.2) | 0.80 |
anti‐TNF‐α = anti‐tumour necrosis factor alpha, IQR = interquartile range.